HIV-1 latency reversing agents converge on phosphoregulation of nuclear protein complexes

Despite the success of antiretroviral therapy (ART), HIV-1 persists in latently infected cells, posing a central barrier to a cure. “Shock-and-kill” strategies using latency-reversing agents (LRAs) have shown some promise in reactivating viral gene expression ex vivo , but have yielded little clinical efficacy, underscoring the need for deeper insight into the molecular mechanisms that govern reactivation. Here, we performed deep quantitative phosphoproteomics of J-Lat 10.6 cells treated with diverse LRAs: SAHA, PMA, or prostratin. We identified 48,476 confidently localized phosphorylation sites mapping to 6,672 proteins, with SAHA inducing the most extensive changes. Regulated phosphoproteins were enriched in chromatin organization, transcription, RNA processing, nuclear transport, and cytoskeletal remodeling. Although LRAs regulated overlapping pathways, they elicited divergent kinase activities and site-specific phosphorylation patterns. A reproducible core of 3,502 phosphorylation sites on 1,432 proteins mapped to 39 nuclear protein complexes, including the spliceosome, Mediator, NF-κB, and RNA polymerase II. Remarkably, 20 protein complexes were phosphoregulated by all three LRAs, but at distinct sites, revealing convergence on shared nuclear machinery through distinct mechanisms. This study provides a comprehensive map of protein complex phosphorylation remodeling during HIV-1 reactivation and highlights signaling mechanisms that could guide the rational design of next-generation LRAs with improved efficacy and reduced toxicity.